Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
ConclusionsSplit tolerance to GUCY2C in cancer patients can be exploited to safely generate antigen-specific cytotoxic CD8+, but not autoimmune CD4+, T cells by Ad5-GUCY2C-PADRE in the absence of pre-existing NAbs to the viral vector.Trial registrationThis trial (NCT01972737) was registered atClinicalTrials.gov on October 30th, 2013.https://clinicaltrials.gov/ct2/show/NCT01972737
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Colon Cancer | Colorectal Cancer | Immunotherapy | Study | Toxicology | Vaccines